CGIX:NSD-Cancer Genetics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.63

Change

0.00 (0.00)%

Market Cap

USD 0.06B

Volume

0.50M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey. Address: 201 Route 17 North, Rutherford, NJ, United States, 07070

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD55.11B 20.60 15.08
MRNA Moderna, Inc

N/A

USD52.85B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

N/A

USD49.45B 15.12 11.87
ALXN Alexion Pharmaceuticals, Inc

N/A

USD33.00B 55.18 32.28
BGNE BeiGene, Ltd

N/A

USD28.45B N/A N/A
SGEN Seagen Inc

N/A

USD27.06B 44.32 37.70
RPRX Royalty Pharma plc

N/A

USD25.83B 22.60 15.41
BNTX BioNTech SE

N/A

USD23.16B -99,999.99 N/A
GMAB Genmab A/S

N/A

USD20.42B 26.59 3.20
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CGIX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 103.25% 97% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 103.25% 97% A+ 97% A+
Trailing 12 Months  
Capital Gain 69.58% 69% D+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.58% 69% D+ 72% C-
Trailing 5 Years  
Capital Gain 115.71% 73% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 115.71% 73% C 69% D+
Average Annual (5 Year Horizon)  
Capital Gain 470.62% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 470.62% 98% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 1,043.86% 2% F 1% F
Risk Adjusted Return 45.09% 73% C 68% D+
Market Capitalization 0.06B 9% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 14.31 18% F 13% F
Price / Cash Flow Ratio -6.87 44% F 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -68.71% 48% F 18% F
Return on Invested Capital -39.08% 68% D+ 22% F
Return on Assets -14.90% 77% C+ 23% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.28 83% B 82% B-
Short Percent 14.93% 13% F 12% F
Beta 2.72 6% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector